Image

Global Sarcoma Drugs Market – Industry Trends and Forecast to 2030

Oncology

Image

Global Sarcoma Drugs Market – Industry Trends and Forecast to 2030

  • Oncology
  • Upcoming Report
  • Feb 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Sarcoma Drugs Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 1,222.20 Million
Diagram Market Size (Forecast Year) USD 2,435.31 Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Sarcoma Drugs Market, By Type (Angiosarcoma, Epithelioid Sarcoma, Liposarcoma, Osteosarcoma, Soft Tissue Sarcoma, Kaposi's Sarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans, Leiomyosarcoma, Others), Drug Therapy (Chemotherapy, Targeted therapy, Immunotherapy, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

 Sarcoma Drugs Market

Sarcoma Drugs Market Analysis and Size

According to the National Cancer Institute, doctors in the United States will diagnose approximately 12,750 cases of soft tissue sarcoma in 2019, with 5,270 people dying from the disease. However, technological advancements in treatment and diagnosis, as well as the rising incidence of sarcoma and other skin cancers, drive market growth. Furthermore, the rising demand for low-cost therapeutics in developing regions presents a growth opportunity for the market.

Data Bridge Market Research analyses that the sarcoma drugs market which was USD 1222.20 million in 2022, is expected to reach USD 2435.31 million by 2030, at a CAGR of 9.00% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Sarcoma Drugs Market Scope and Segmentation  

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Angiosarcoma, Epithelioid Sarcoma, Liposarcoma, Osteosarcoma, Soft Tissue Sarcoma, Kaposi's Sarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans, Leiomyosarcoma, Others), Drug Therapy (Chemotherapy, Targeted therapy, Immunotherapy, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany)

Market Opportunities

  • Possession of a Strong Drug Pipeline

Market Definition

Sarcoma is a type of cancer that can occur in any part of the body. Sarcoma begins in the bone and soft tissues and then spreads to other parts of the body. Although there are over 50 different types of sarcoma, they can be divided into two categories: soft tissue sarcoma and bone sarcoma, also known as osteosarcoma. Sarcoma is uncommon in adults. According to the American Society of Clinical Oncology, it accounts for about 1% of all adult cancers (ASCO). It is more prevalent in children, accounting for about 15% of all pediatric cancers.

Sarcoma Drugs Market Dynamics

Drivers

  • Growing use of immunotherapy for the treatment of sarcoma

Stimulating or boosting the natural defences of a patient's immune system so that it works harder or smarter to find and attack cancer cells. Immunotherapy has recently become an important part of the treatment of certain types of cancer. New immunotherapy treatments and new ways of working with the immune system are being tested and approved at a rapid pace. Immunotherapy is more effective for some cancers than others. During the forecast period, these factors are expected to drive the growth of the sarcoma drugs market.

  • Increasing Cancer Prevalence to support Sarcoma Drugs

Cancer has surpassed cardiovascular disease as the world's second leading cause of death. Environmental factors such as tobacco use, urbanization, changing dietary patterns, and an extended post-reproductive lifespan all contribute to this phenomenon.  Cancer is a growing burden, according to the World Health Organization (WHO), with the number of new cancer cases expected to rise from 18.1 million in 2018 to 29.4 million by 2040. As a result, rising cancer prevalence is expected to drive demand for global oncology cancer drugs during the forecast period. Furthermore, rising cancer awareness is expected to benefit the sarcoma drugs market in the coming years.

Opportunities

  • Possession of a Strong Drug Pipeline to Fuel Sarcoma Drugs

Cancer treatment is evolving at a rapid pace. The R&D pipeline is producing a slew of novel treatments, many of which are frequently combined with other new or existing medications. Many pharmaceutical companies are investing in novel cancer drug research. For instance, Pfizer acquired Array BioPharma in 2019 with the goal of expanding its oncology presence and pipeline, beginning with an approved melanoma combination therapy that is currently in a phase 3 trial for a type of metastatic colorectal cancer. This, combined with an rising preference for biosimilar and biologics entering the market, is expected to propel the sarcoma drugs market forward.

Restraints/Challenges

  • Lack of Skilled Professionals

Lack of trained healthcare professionals who are unaware of the treatment methods for this disease may limit the growth of the global sarcoma drugs market during the forecast period.

This sarcoma drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the sarcoma drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In 2020, Junshi Biosciences, a global biopharmaceutical company, received FDA approval for Orphan Drug designation for toripalimab to treat soft tissue sarcoma. This approval is expected to assist the company in marketing new products and attracting new customers, resulting in increased revenue.

Global Sarcoma Drugs Market Scope

The sarcoma drugs market is segmented on the basis of type, drug therapy, drug type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Angiosarcoma
  • Epithelioid Sarcoma
  • Liposarcoma
  • Osteosarcoma
  • Soft Tissue Sarcoma
  • Kaposi's Sarcoma
  • Chondrosarcoma
  • Dermatofibrosarcoma Protuberans
  • Leiomyosarcoma
  • Others

Drug Therapy

  • Chemotherapy
  • Doxorubicin
  • Epirubicin
  • Ifosfamide
  • Eribulin
  • Temozolomide
  • Methotrexate
  • Others
  • Targeted therapy
  • Olaratumab
  • Imatinib
  • Pazopanib
  • Pexidartinib
  • larotrectinib
  • Others
  • Immunotherapy
  • Pembrolizumab
  • Others

 Drug Type

  • Branded
  • Lartruvo
  •  Gleevec
  • Votrient
  • Tazverik
  • Turalio
  • Vitrakvi
  • keytruda
  • Others
  • Generic

 End-Users

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

 Distribution Channel

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Sarcoma Drugs Market Regional Analysis/Insights

The sarcoma drugs market is analyzed and market size insights and trends are provided by country, type, drug therapy, drug type, end-users and distribution channel as referenced above.

The countries covered in the sarcoma drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the sarcoma drugs market due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to constant rise in the incidence of cancer coupled with increased demand for cost-efficient therapeutics.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The sarcoma drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for sarcoma drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the sarcoma drugs market. The data is available for historic period 2011-2021.

Competitive Landscape and Sarcoma Drugs Market Share Analysis

The sarcoma drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to sarcoma drugs market.

Some of the major players operating in the sarcoma drugs market are:

  • Johnson & Johnson Private Limited (U.S.)
  • Abbott (U.S.)
  • AbbVie Inc. (U.S.)
  • Bausch Health Companies Inc. (Canada)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Pfizer Inc (U.S.)
  • Mylan N.V. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc. (U.K.)
  • Bayer AG (Germany) 


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The sarcoma drugs market value was USD 1222.20 million in 2022.
The sarcoma drugs market is projected to grow at a CAGR of 9.00% during the forecast period of 2023-2030.
The Sarcoma Drugs Market is bifurcated by type, drug therapy, drug type, end-users, and distribution channel.
North America dominates the sarcoma drugs market due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials